Zobrazeno 1 - 10
of 167
pro vyhledávání: '"Caroline Dutriaux"'
Autor:
Céline Eldani, Marie Kostine, Maxime Faure, Estibaliz Lazaro, Claire Rigothier, Jean Baptiste Hiriart, Bérénice Teulières, Florian Poullenot, Magalie Haissaguerre, Maeva Zysman, Rémi Veillon, Charlotte Vergnenegre, Nahema Issa, Charlotte Domblides, Sorilla Mary-Prey, Marie Beylot-Barry, Anne Pham-Ledard, Caroline Dutriaux, Guilhem Sole, Fanny Duval, Emilie Gerard
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation 1. While guidelines recommend discontinuing ICIs for grad
Externí odkaz:
https://doaj.org/article/dc9286fc8fa7429d8cc121e94b05face
Autor:
Samuel Bitoun, Marie Kostine, Christophe Richez, Thomas Barnetche, Thierry Schaeverbeke, Gael Mouterde, Marie-Elise Truchetet, Maéva Zysman, Amaury Daste, Sorilla Prey, Alice Tison, Rémi Veillon, Caroline Dutriaux, Anne Pham-Ledard, Marie Beylot-Barry, Marine Gross-Goupil, Félix Lefort, Alexandra Ladouceur, Emilie Gerard, Charlotte Domblides, Baptiste Sionneau, Mathieu Larroquette
Publikováno v:
RMD Open, Vol 9, Iss 4 (2023)
Objective Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety
Externí odkaz:
https://doaj.org/article/dd729db8de80406ebd7112cf82a7704c
Autor:
David Russo, Stéphane Dalle, Olivier Dereure, Laurent Mortier, Sophie Dalac-Rat, Caroline Dutriaux, Marie-Thérèse Leccia, Delphine Legoupil, Henri Montaudié, Eve Maubec, Julie De Quatrebarbes, Jean-Philippe Arnault, Florence Granel Brocard, Philippe Saïag, Brigitte Dreno, Clara Allayous, Bastien Oriano, Wendy Lefevre, Céleste Lebbé, Lise Boussemart
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe tumor mutational burden (TMB) is high in melanomas owing to UV-induced oncogenesis. While a high TMB is a predictive biomarker of response to PD-1 inhibitors, it may be associated with the rise of resistant clones to targeted therapy ov
Externí odkaz:
https://doaj.org/article/f844a1fc7d06416ea3d2882e024c7f02
Autor:
Marguerite Kandel, Aurélie Bardet, Stéphane Dalle, Clara Allayous, Laurent Mortier, Bernard Guillot, Caroline Dutriaux, Marie-Thérèse Leccia, Sophie Dalac, Henri Montaudie, Philippe Saiag, Delphine Legoupil, Florence Brunet-Possenti, Jean-Philippe Arnault, Julie De Quatrebarbes, Marie Beylot-Barry, Eve Maubec, Thierry Lesimple, François Aubin, Jean-Jacques Grob, Florence Granel-Brocard, Pierre-Emmanuel Stoebner, Alain Dupuy, Brigitte Dreno, Stefan Michiels, Céleste Lebbe, Isabelle Borget
Publikováno v:
Current Oncology, Vol 29, Iss 12, Pp 9255-9270 (2022)
Nine drugs have been marketed for 10 years for the treatment of advanced melanoma (AM). With half of patients reaching a second line, the optimal sequence of treatments remains unclear. To inform policy-makers about their efficiency, we performed a c
Externí odkaz:
https://doaj.org/article/029219c40f474f67aac932d94f25d323
Autor:
Léa Dousset, MD, Alize Pacaud, MD, Thomas Barnetche, PhD, Marie Kostine, MD, PhD, Caroline Dutriaux, MD, Anne Pham-Ledard, MD, PhD, Marie Beylot-Barry, MD, PhD, Emilie Gérard, MD, Sorilla Prey, MD, PhD, Nicolas Andreu, BSc, Katia Boniface, PhD, Julien Seneschal, MD, PhD
Publikováno v:
JAAD International, Vol 5, Iss , Pp 112-120 (2021)
Background: Clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 (PD-1) remain unknown. Objective: To better characterize the occurrence of vitiligo in patients receiving anti–PD-1. Methods: The present sin
Externí odkaz:
https://doaj.org/article/76be4dd06db242e08a19309ca7ae10ba
Autor:
Caroline Robert, Helena Escuin-Ordinas, Juan Martin-Liberal, Miguel Sanmamed, Stephane Dalle, Ana Arance, Marya Chaney, Sorilla Prey, Alfonso Berrocal, Caroline Dutriaux, Iván Márquez Rodas, Philippe Saiag, Luis de la Cruz Merino, Juan Rodríguez-Moreno, Eduardo Castañón Álvarez, Pablo Cerezuela-Fuentes, Henry Montaudie, María González Cao, Julie Charles, María Pilar López Criado, Enrique de Miguel, Elisa Funk-Brentano, Roberto Huertas, Delvys Rodríguez Abreu, Eva Muñoz Couselo, Javier Sánchez López, Sonia Maciá
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/cfa232992c194eb9b490f0ff34e0deec
Autor:
Ondine Becquart, Bastien Oriano, Stéphane Dalle, Laurent Mortier, Marie Thérèse Leccia, Caroline Dutriaux, Sophie Dalac, Henri Montaudié, Julie De Quatrebarbes, Florence Brunet-Possenti, Philippe Saiag, Thierry Lesimple, Marie Beylot-Barry, Francois Aubin, Pierre-Emmanuel Stoebner, Jean-Philippe Arnault, Brigitte Dreno, Raphael Porcher, Celeste Lebbe, Bernard Guillot
Publikováno v:
Cancers, Vol 13, Iss 12, p 3042 (2021)
Purpose: Melanoma’s incidence is increasing, and elderly people could be significantly impacted since the majority occurs in people over 65 years of age. Combined BRAF and MEK targeted therapies (TT) are current standard regimen for BRAF mutated me
Externí odkaz:
https://doaj.org/article/52e1bc0b33964b3eb467b92106cad926
Autor:
Sandra Huynh, Laurent Mortier, Caroline Dutriaux, Eve Maubec, Marie Boileau, Olivier Dereure, Marie-Therese Leccia, Jean-Philippe Arnault, Florence Brunet-Possenti, Francois Aubin, Brigitte Dreno, Marie Beylot-Barry, Celeste Lebbe, Wendy Lefevre, Julie Delyon
Publikováno v:
Cancers, Vol 12, Iss 6, p 1666 (2020)
Despite significant progress in melanoma survival, therapeutic options are still needed in case of progression under immune checkpoint inhibitors (ICI), and resistance to targeted therapies (TT) in BRAF-mutated melanomas. This study aimed to assess t
Externí odkaz:
https://doaj.org/article/d88dc03563864abba37b6f3eee882c09
Autor:
Celeste Lebbé, Caroline Dutriaux, Thierry Lesimple, Willem Kruit, Joseph Kerger, Luc Thomas, Bernard Guillot, Filippo de Braud, Claus Garbe, Jean-Jacques Grob, Carmen Loquai, Virginia Ferraresi, Caroline Robert, Paul Vasey, Robert Conry, Richard Isaacs, Enrique Espinosa, Armin Schueler, Giorgio Massimini, Brigitte Dréno
Publikováno v:
Cancers, Vol 12, Iss 7, p 1727 (2020)
This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-
Externí odkaz:
https://doaj.org/article/fb6a7c3b4d9c40bfbbb29e6cefdef71c
Autor:
Tristan Pigné, Marie Lévy, Océane Ducharme, Caroline Dutriaux, Emilie Gerard, Anne Pham-Ledard, Marie Beylot-Barry, Sorilla Prey
Publikováno v:
Melanoma Research. 33:252-256